Application of combination of CB-839 and atorvastatin calcium in preparation of medicine for treating heart failure
By setting the mass ratio of CB-839 and atorvastatin calcium to 33:1 and using it as a heart failure drug, the problems of limited treatment effects and side effects of central failure in the existing technology have been solved, and significant improvement in the efficacy and liver are achieved. Functional protection.
Patent Information
- Application Number
- CN202411077255.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-15
AI Technical Summary
The existing heart failure treatment drugs have limited effect on improving heart function, and long-term use of atorvastatin calcium has problems with drug resistance, liver function impairment and side effects. The treatment effect of CB-839 alone is also limited in heart failure.
CB-839 is used in combination with atorvastatin calcium, with a preferred mass ratio of 33:1, as a combination of drugs for treating heart failure, reducing inflammatory cell infiltration, myocardial fibrosis and apoptosis by inhibiting glutaminease, improving Heart function.
It significantly improves the therapeutic effect of heart failure, and has a three-fold increase in efficacy compared with drugs alone, without obvious toxic side effects, and has a protective effect on liver function, providing a better choice of heart medication.
Smart Images

Figure CN118948854A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology and relates to the application of CB-839 (Telaglenastat) combined with atorvastatin calcium in preparing a medicine for treating heart failure. Background Art
[0002] Heart failure (HF) is a clinical syndrome characterized by a series of corresponding symptoms and signs caused by stiff or weak myocardium, decreased blood pumping capacity, and inability to meet the body's needs. HF does not mean that the heart cannot work at all, but that it cannot function normally. Because the heart cannot pump enough blood into the arterial system, the organs and tissues suffer from ischemia and hypoxia, resulting in impaired activity endurance, dyspnea, weakness, and decreased energy; at the same time, because the blood in the venous system cannot be fully recovered, peripheral venous congestion occurs, resulting in weight gain, edema, abdominal swelling, or a feeling of fullness. Pathological damage to the myocardium in HF includes early myocardial hypertrophy, mid-term myocardial damage or necrosis, and late myocardial pathological remodeling. According to epidemiological surveys, there are currently 40 million people suffering from HF worldwide. With the unremitting efforts of predecessors, the treatment strategies and medical means of HF have made great progress and developed rapidly, but HF is still one of the most common, expensive, most disabling and most deadly diseases encountered by doctors in primary and secondary care. Therefore, developing new drugs that can effectively treat heart failure is one of the key issues that need to be urgently addressed in cardiology research.
[0003] Atorvastatin calcium (At-Ca) is an HMG-CoA reductase inhibitor that can reduce the cholesterol content in the blood and is a first-line drug for the clinical treatment of hyperlipidemia. In recent years, a large number of clinical experiments and basic experimental studies have shown that At-Ca can significantly improve the cardiac function of patients with heart failure, improve the quality of life, and increase the survival rate, which has long-term benefits for patients with heart failure. However, long-term use of At-Ca also faces side effects and adverse reactions such as drug resistance, impaired liver function, gastrointestinal irritation, dizziness, and nausea. At the same time, the therapeutic effect of medication alone on heart failure is limited and cannot achieve the ideal therapeutic effect.
[0004] CB-839 (Telaglenastat) is an effective, orally bioavailable, selective inhibitor of glutaminase (glutaminase 1, GLS1) splice variants (KGA and GAC), which inhibits glutamine cleavage. Glutamine metabolism is the main energy source for tumor cells. Inhibiting glutaminase can effectively inhibit tumor cell growth and proliferation, achieving the effect of treating tumors. Therefore, CB-839 is mainly used in the field of tumors. Summary of the invention
[0005] The present invention found that CB-839 has the function of treating heart failure through the aortic arch stenosis (TAC) heart failure mouse model, and its effect is significantly better than other types of GLS1 inhibitors. The present invention also found that the combined treatment effect of CB-839 and At-Ca, a first-line drug for the treatment of heart failure, is significantly better than the single drug, and the optimal mass ratio of the combined treatment of the two is 33:1. Based on the above discovery, the purpose of the present invention is to provide the use of CB-839 (Telaglenastat) in the preparation of drugs for the treatment of heart failure. The purpose of the present invention is also to provide the use of CB-839 in combination with atorvastatin calcium (At-Ca) in the preparation of drugs for the treatment of heart failure.
[0006] The purpose of the present invention is achieved through the following technical solutions:
[0007] Application of CB-839 in the preparation of drugs for treating heart failure.
[0008] Use of a composition containing CB-839 in preparing a drug for treating heart failure.
[0009] Application of CB-839 and atorvastatin calcium in the preparation of a drug for treating heart failure, wherein the mass ratio of CB-839 to atorvastatin calcium is preferably 1-100:1, more preferably 30-100:1, further preferably 30-35:1, and most preferably 33:1.
[0010] Use of a composition containing CB-839 and atorvastatin calcium in the preparation of a drug for treating heart failure, wherein the mass ratio of CB-839 to atorvastatin calcium is preferably 1-100:1, more preferably 30-100:1, further preferably 30-35:1, and most preferably 33:1.
[0011] A drug for treating heart failure, comprising CB-839 and atorvastatin calcium, and further comprising excipient components acceptable in pharmaceutical preparation, wherein the mass ratio of CB-839 to atorvastatin calcium is preferably 1-100:1, more preferably 30-100:1, further preferably 30-35:1, and most preferably 33:1.
[0012] The present invention found that CB-839 has significant therapeutic effects in relieving clinical symptoms, improving cardiac function, and increasing physical strength in the treatment of heart failure, which illustrates the function of CB-839 in reducing inflammatory cell infiltration, myocardial fibrosis, and myocardial tissue cell apoptosis and relieving myocardial pathological damage. And compared with other glutaminase inhibitors, the effect is most obvious. The present invention also found that the combined use of CB-839 and At-Ca, a first-line clinical treatment drug for heart failure, has an efficacy of about 3 times that of the single drug, far exceeding the single drug, and has no obvious toxic side effects. The optimal ratio of CB-839 and At-Ca for combined use is 33:1. In summary, CB-839 (Telaglenastat) can be used as a pharmaceutical preparation for heart failure. Therefore, the present invention provides the use of CB-839 in the preparation of heart failure drugs, which has the following advantages and effects relative to the prior art:
[0013] (1) CB-839 is a small molecule compound that is orally bioavailable, easily absorbed, and can easily reach the heart to exert its effects;
[0014] (2) CB-839 has no significant inhibitory effect on liver glutaminase 2 and has relatively little liver toxicity;
[0015] (3) The combination of CB-839 and atorvastatin calcium has no obvious toxic side effects and even has a certain protective effect on liver function;
[0016] (4) CB-839 has excellent stability, providing multiple options for the administration and delivery routes of the compound. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 It is the chemical structure diagram of CB-839 (Telaglenastat) and Atorvastatin Calcium (At-Ca).
[0018] Figure 2 This is a comparison chart of the effects of CB839 (Telaglenastat) and other glutaminase inhibitors.
[0019] Figure 3 This is a comparison of the cardiac function improvement effects of CB839 (Telaglenastat) and other glutaminase inhibitors in treating mice with hypertrophic cardiomyopathy and chronic heart failure.
[0020] Figure 4 This is a histopathological comparison of CB839 (Telaglenastat) and other glutaminase inhibitors in treating hypertrophic cardiomyopathy and chronic heart failure mice to improve myocardial tissue pathological damage.
[0021] Figure 5This is a graph showing the improvement in cardiac function of mice with chronic heart failure and hypertrophic cardiomyopathy treated with the combination of CB839 (Telaglenastat) and atorvastatin calcium.
[0022] Figure 6 This is a histopathological image showing that the combined treatment of CB839 (Telaglenastat) and atorvastatin calcium improved myocardial tissue pathological damage in mice with chronic heart failure and hypertrophic cardiomyopathy. DETAILED DESCRIPTION
[0023] The present invention provides an effective, orally bioavailable, selective glutaminase splice variant (KGA and GAC) inhibitor CB-839 for use in preparing a drug for treating heart failure, and its combined use with atorvastatin calcium in preparing a drug for treating heart failure. The combined treatment of heart failure has a better effect, and the optimal mass ratio of CB-839 to atorvastatin calcium is 33:1. The molecular formula of the inhibitor CB-839 in the present invention is C 26 H 24 F3N7O3S.
[0024] The test compounds used in the following examples of the present invention were all supplied by Selleck, stored at -20°C in powder form and stored at -80°C after dissolution. The specific information is as follows:
[0025] CB-839 (Telaglenastat), molecular formula: C 26 H 24 F3N7O3S, production batch number: 1439399-58-2.
[0026] BPTES, molecular formula: C 24 H 24 N6O2S3, production batch number: 314045-39-1.
[0027] UPGL00004(UPGL), molecular formula: C 25 H 26 N8O2S2, production batch number: 1890169-95-5.
[0028] GK921, molecular formula: C 21 H 20 N4O, production batch number: 1025015-40-0.
[0029] 6-Diazo-5-oxo-L-norleucine (DON), molecular formula: C6H9N3O3, production batch number: 157-03-9.
[0030] Atorvastatin Calcium(At-Ca), molecular formula: 2(C33 H 34 FN2O5).Ca, production batch number: 134523-03-8.
[0031] Preparation of the test compound solution:
[0032] CB-839, weigh an appropriate amount of powder and dissolve it in DMSO.
[0033] BPTES, weigh an appropriate amount of powder and dissolve it in DMSO.
[0034] UPGL, weigh an appropriate amount of powder and dissolve it in DMSO.
[0035] GK921, weigh an appropriate amount of powder and dissolve it in DMSO.
[0036] DON, weigh an appropriate amount of powder, dissolve it in a small amount of sterile water, and then dilute it with physiological saline (volume of sterile water: volume of physiological saline = 1:9), and filter it through a 0.22 μm filter.
[0037] At-Ca, weigh an appropriate amount of powder and dissolve it in DMSO.
[0038] Experimental animals and experimental methods used in the following examples:
[0039] This invention uses specific pathogen-free (SPF)-grade male C57BL / 6J mice. The mice were purchased from Wuhan Youdu Biotechnology Co., Ltd. License number: SCXK(E)2021-0025, experimental animal certificate number: NO.422022500004729. The mice were raised in an SPF-grade animal room with a 12-hour light - 12-hour dark cycle, sufficient feed and water, and constant humidity and temperature. After 1 week of adaptive feeding after the mice arrived, a chronic heart failure model animal model was constructed by transverse aortic constriction (TAC). TAC is a recognized, mature, and effective method for creating heart failure animal models in cardiology research, and C57BL / 6J mice are a commonly used mouse strain for heart failure models.
[0040] Surgical treatment:
[0041] 1) Sham operation group: 8 hours before the operation, the mice were fasted from drinking water and injected intraperitoneally with 0.1g / mL sodium pentobarbital at a dose of 50mg / kg. After the mice were fully anesthetized and breathing was stable, the mice were fixed on the operating platform with their long axis vertical and their limbs stretched with medical breathable tape. Hair in the surgical area of the chest and neck was removed with depilatory cream, and tracheal intubation was performed. The parameters of the small animal ventilator were set as follows: frequency 100 times / minute, tidal volume 1mL. Medical iodine was used to disinfect the skin of the prepared area 3 times. Under the irradiation of a shadowless lamp, ophthalmic scissors were used to cut the skin horizontally about 0.5cm at the midpoint of the line connecting the upper limbs. The subcutaneous muscles were bluntly separated with ophthalmic forceps, the sternum was cut, the chest was propped open, and the thymus was gently and bluntly separated. The aortic arch was visible, and the aortic arch was separated from the surrounding soft tissues. Then, the muscles and skin were sutured layer by layer and disinfected with iodine. After the operation, the animals were placed on an electric blanket until they woke up from anesthesia. Meloxicam injection 4 mg / kg was injected subcutaneously every day for analgesia, and gentamicin sulfate injection 5 mg / kg was injected intramuscularly for anti-infection, once every 12 hours for three consecutive days.
[0042] 2) TAC group: The preoperative steps were the same as above. After the aortic arch was separated during the operation, the 28G padding needle and the aortic arch were ligated simultaneously using 6-0 surgical thread. The padding needle was slowly and gently withdrawn, and the excess thread was cut off. The subsequent experimental steps were the same as 1).
[0043] One week after surgery, under normal temperature, 4-5% isoflurane gas was used to induce anesthesia, and 1-2% isoflurane was used to maintain anesthesia. Cardiac ultrasound examination was performed, and the presence of obvious left ventricular hypertrophy indicated a successful operation (TAC group).
[0044] The mice were randomly divided into groups according to the experimental needs, and compound treatment was started 4 weeks after surgery. The experimental endpoint was reached 8 weeks after surgery. After exercise endurance testing and ultrasound observation, the mice were weighed, peripheral blood was collected under sodium pentobarbital anesthesia, the mice were killed, heart samples were taken out and weighed, and the samples were preserved for subsequent testing.
[0045] End point detection indicators:
[0046] 1) Activity endurance experiment: maximum running distance of mice.
[0047] 2) Cardiac ultrasound: left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular end-diastolic dimension (LVDEV), and left ventricular posterior wall at diastole (LVPW; d).
[0048] 3) Heart-to-weight ratio index: heart weight divided by body weight.
[0049] 4) Peripheral serum brain natriuretic peptide and amino-terminal pro-brain natriuretic peptide: Both are recognized and widely used clinical markers of heart failure. The peripheral blood of mice was collected and centrifuged to separate the serum. The corresponding content in the peripheral serum of mice was detected according to the instructions of the reagent manufacturer. The kits used were: mouse brain natriuretic peptide (BNP) enzyme-linked immunosorbent assay kit, model: E-EL-M0204, manufacturer: Elabscience; mouse amino-terminal pro-brain natriuretic peptide (NT-proBNP) enzyme-linked immunosorbent assay kit, model: E-EL-M0834, manufacturer: Shanghai Youkewei Biotechnology Co., Ltd.
[0050] 5) Peripheral serum alanine aminotransferase (ALT): A widely recognized and clinically used marker of liver function impairment. The peripheral blood of mice was collected and centrifuged to separate the serum. The corresponding content in the peripheral serum of mice was detected according to the instructions of the reagent manufacturer. The kit used was: Mouse Alanine Transaminase / Alanine Transaminase (ALT / GPT) ELISA Kit, model: YKW-20606, manufacturer: Elabscience.
[0051] 6) Myocardial tissue staining: Hematoxylin-eosin staining (HE staining), trichrome staining (Masson staining), wheat germ agglutinin (WGA) staining, and Tunel immunofluorescence staining.
[0052] Data statistics: Image J was used for image analysis. Data were expressed as Mean ± SEM, and Graphpad Prism 9.0 was used for statistical analysis and drawing. One-way ANOVA Brown-Forsythe and Welch ANOVA tests were used for data analysis, and P < 0.05 was considered statistically significant.
[0053] Based on the above experimental method, the present invention is further described below in conjunction with specific examples and result drawings, but the embodiments of the present invention are not limited thereto.
[0054] Example 1
[0055] CB-839 (Telaglenastat) is a selective inhibitor of glutaminase splice variants (KGA and GAC) with a molecular formula of C 26 H 24 The molecular structure of F3N7O3S, CB-839 is shown in Figure 1 A; At-Ca is an HMG-CoA reductase inhibitor with a molecular formula of 2(C 33 H 34 FN2O5).Ca, molecular structure see Figure 1 B.
[0056] Male, 6-week-old C57BL / 6J mice were randomly divided into 7 groups, 25 mice in each group (n=25), and each group of mice was treated as follows:
[0057] Control group (Ctrl): no special treatment;
[0058] CB-839 treatment group (CB-839): weigh appropriate amount of powder, dissolve in DMSO, and administer by intraperitoneal injection at 3 mg / kg, three times a week;
[0059] BPTES treatment group (BPTES): weigh an appropriate amount of powder, dissolve in DMSO, and administer intraperitoneal injection at 3 mg / kg, three times a week;
[0060] UPGL00004 treatment group (UPGL): weigh an appropriate amount of powder, dissolve it in DMSO, and administer it by intraperitoneal injection at 1 mg / kg, three times a week;
[0061] GK921 treatment group (GK921): weigh appropriate amount of powder, dissolve in DMSO, and administer intraperitoneal injection at 2 mg / kg, three times a week;
[0062] DON treatment group (DON): Weigh an appropriate amount of powder, dissolve it in a small amount of sterile water, dilute it with normal saline (sterile water volume: normal saline volume = 1:9), filter it with a 0.22 μm filter, and administer it by intraperitoneal injection at 2 mg / kg, three times a week.
[0063] The above treatment lasted for 4 weeks. At the beginning of treatment and every week thereafter, 5 mice were killed by cervical dislocation in each group, and the hearts were removed for real-time quantitative PCR to detect the expression of GAC mRNA and KGA mRNA. In the last week, the mice were killed and the heart tissues were taken for protein electrophoresis (Western blotting) and real-time quantitative PCR to detect the expression of GAC and KGA proteins and mRNA.
[0064] The primer sequences for GAC and KGA in real-time quantitative PCR are as follows:
[0065] mouse-GAC-Forward:CACCGCGCCGGACTCCACCCGTGGT,
[0066] mouse-GAC-Reverse:AAACACCACGGGTGGAGTCGCGCGC;
[0067] mouse-KGA-Forward: ACTGGAGATGTGTCTGCCCTCCGAAG,
[0068] mouse-KGA-Reverse: CCAAAGTGTAGTGCTTCATCCATGGGG.
[0069] The results of real-time quantitative PCR are shown in the attached Figure 2 As shown in A and B, the expression of GAC mRNA and KGA mRNA in the treatment group decreased gradually over time compared with the control group, reaching the lowest level at the 4th week (P < 0.05). The CB-839 treatment group had the most obvious inhibitory effect, and the rate of decline was significantly faster than that of the other glutamine inhibitor treatment groups. The results of the 4th week showed that the expression of GAC mRNA and KGA mRNA in the CB-839 group was significantly decreased compared with the control group (P values were < 0.0001). Western blotting was performed on myocardial tissue at the 4th week (Appendix Figure 2 C, D, E), the results showed that the expression of GAC and KGA proteins in the treatment group was significantly decreased compared with the control group (all P values were <0.05), and the CB-839 compound treatment group had the most significant decrease (P <0.0001).
[0070] The experimental results of Example 1 show that CB-839 significantly inhibits the expression of glutaminase in myocardial tissue and has the fastest onset and the best effect compared with other types of inhibitors.
[0071] Example 2
[0072] Figure 3 A is a schematic diagram of mouse modeling and drug administration. As shown in the figure, the mouse was surgically modeled at 6 weeks of age, and the compound treatment was started at 4 weeks after surgery. The drug administration method was the same as in Example 1, and the experimental endpoint was reached at 8 weeks after surgery. In this example, the mice were randomly divided into the following 8 groups (n=5-10):
[0073] ①Control group (Normal): no special treatment;
[0074] ②Sham operation group: sham operation;
[0075] ③TAC group: received TAC surgery;
[0076] ④TAC+CB-839 group: TAC surgery was performed, and 3 mg / kg was intraperitoneally injected three times a week starting from the 4th week;
[0077] ⑤TAC+BPTES group: TAC surgery was performed, and 3 mg / kg was intraperitoneally injected three times a week starting from the 4th week;
[0078] ⑥TAC+UPGL group: TAC surgery was performed, and 1 mg / kg was intraperitoneally injected three times a week starting from the 4th week;
[0079] ⑦TAC+GK921 group: TAC surgery was performed, and 2 mg / kg was intraperitoneally injected three times a week starting from the 4th week;
[0080] ⑧TAC+DON group: TAC surgery was performed, and the drug was intraperitoneally injected at 2 mg / kg three times a week starting from the 4th week.
[0081] The volume of each intraperitoneal injection of each mouse was controlled to be about 100 μL (± 5 μL). Drug treatment lasted for 4 weeks. After the 8th week after surgery, exercise endurance test and cardiac ultrasound examination were performed. Peripheral blood and heart were collected under anesthesia. The heart tissue was embedded, fixed, dewaxed, etc. to prepare tissue wax blocks, and HE, Masson, immunofluorescence and Tunel staining were performed. The results are shown in Tables 1-4 and Figure 3 , 4 .
[0082] Table 1 Cardiac ultrasound parameters of mice in each group in Example 2 (Mean ± SEM, n = 5)
[0083] project LVEF (%) LVFS(%) LVEDV (μL) LVPW;d(mm) Normal 72.58±1.90 41.40±1.55 74.39±2.84 0.79±0.14 Sham 70.80±2.18 42.48±2.43 75.92±3.10 0.64±0.06 TAC <![CDATA[34.85±2.71 **** ]]> <![CDATA[20.81±2.15 *** ]]> <![CDATA[34.02±3.35 **** ]]> <![CDATA[2.77±0.11 **** <!-- 5 -->]]> TAC+CB-839 <![CDATA[49.52±0.94 ### ]]> <![CDATA[28.64±1.39 ## ]]> <![CDATA[50.24±1.32 ### ]]> <![CDATA[1.94±0.11 #### ]]> TAC+BPTES <![CDATA[43.21±2.81 # ]]> <![CDATA[26.28±0.92 # ]]> <![CDATA[42.33±1.72 # ]]> <![CDATA[2.30±0.12 ## ]]> TAC+UPGL <![CDATA[42.24±1.07 # ]]> <![CDATA[26.42±0.95 ## ]]> <![CDATA[42.22±5.86 # ]]> <![CDATA[2.25±0.10 ## ]]> TAC+GK921 39.52±1.91 24.19±1.19 42.62±0.97 2.57±0.09 TAC+DON 35.98±2.59 22.84±1.47 37.99±3.86 2.58±0.13
[0084] ***P<0.001vs Sham, ****P<0.0001vs Sham; #P<0.05vs TAC, ##P<0.01vs TAC, ###P<0.001vs TAC, ####P<0.0001vs TAC, one-way ANOVA test.
[0085] Figure 3 B is the representative cardiac ultrasound image of each group; as shown in Table 1 and Figure 3As shown in B-F, compared with the control group, there were no significant differences in the various cardiac function indicators of the mice in the Sham group (all P values>0.05), indicating that sham surgery did not affect the cardiac function and heart morphology of the mice; compared with the Sham group, the cardiac function LVEF (34.85±2.71 vs 70.80±2.18, P<0.0001), LVFS (20.81±2.15 vs 42.48±2.43, P<0.001), and LVEDV (34.02±3.35 vs 75.92±3.10, P<0.0001) of the mice in the TAC group were significantly decreased, and LVPW;d (2.77±0.11 vs 0.64±0.06, P<0.0001), indicating that the cardiac function of mice in the TAC group was decreased and myocardial hypertrophy was observed, suggesting that the TAC chronic heart failure mouse model was successfully established. Compared with the TAC group, the cardiac function LVEF (49.52±0.94vs 34.85±2.71, P<0.001), LVFS (28.64±1.39vs 20.81±2.15, P<0.01), and LVEDV (50.24±1.32vs 34.02±3.35, P<0.001) of the TAC+CB-839 group were significantly increased, and the LVPW;d (1.94±0.11vs 2.77±0.11, P<0.0001) was significantly decreased in the TAC+CB-839 group, indicating that CB-839 significantly improved the cardiac function decline and reduced myocardial hypertrophy in heart failure mice. Compared with other glutaminase inhibitors, CB-839 has the best therapeutic effect.
[0086] Table 2 Heart weight and body weight index of mice in each group (n=5)
[0087]
[0088] ****P<0.0001vs Sham; ##P<0.01vs TAC, ###P<0.001vs TAC, one-way ANOVA test.
[0089] As shown in Table 2 and Figure 3As shown in G, compared with the control group, the heart weight / body weight index of mice in the Sham group did not change significantly (3.84±0.20 vs 3.79±0.16, P>0.05), indicating that sham surgery did not affect the size of the mouse heart; compared with the Sham group, the heart weight / body weight index of mice in the TAC group increased significantly (5.72±0.14 vs 3.84±0.20, P<0.0001), indicating that the heart of TAC mice was enlarged and myocardial hypertrophy; compared with the TAC group, the heart weight / body weight index of mice in the TAC+CB-839 group decreased significantly (4.94±0.14 vs 5.72±0.14, P<0.001), proving that CB-839 can improve the enlargement of the heart in mice with chronic heart failure. And compared with other glutaminase inhibitors, CB-839 has the most significant improvement.
[0090] Table 3 Maximum running distance of mice in each group (n=10)
[0091]
[0092] ****P<0.0001vs Sham; ###P<0.001vs TAC, ####P<0.0001vs TAC, one-way ANOVA test.
[0093] As shown in Table 3 and Figure 3 As shown in Figure H, compared with the control group, the maximum running distance of mice in the Sham group did not change significantly (213.98±7.04 vs 219.21±6.33, P>0.05), indicating that sham surgery did not affect the exercise endurance of mice; compared with the Sham group, the maximum running distance of mice in the TAC group decreased significantly (79.92±5.64 vs 213.98±7.04, P<0.0001), indicating that the exercise endurance of TAC mice decreased and the symptoms of heart failure were aggravated; compared with the TAC group, the maximum running distance of mice in the TAC+CB-839 group increased (127.37±6.88 vs 79.92±5.64, P<0.0001), proving that CB-839 can improve the activity tolerance of mice with chronic heart failure and improve the symptoms of heart failure. Compared with other glutaminase inhibitors, CB-839 has the most obvious therapeutic effect.
[0094] Table 4 Peripheral serum heart failure markers brain natriuretic peptide (BNP) and amino-terminal pro-brain natriuretic peptide (NT-proBNP) values in each group of mice (n=10)
[0095]
[0096] ****P<0.0001vs Sham; #P<0.05vs TAC, ##P<0.01vs TAC, ###P<0.001vs TAC, ####P<0.0001vs TAC, one-way ANOVA test.
[0097] As shown in Table 4 and Figure 3 As shown in I and J, compared with the control group, there was no significant change in BNP (27.65±6.24 vs 26.23±4.11, P>0.05) and NT-pro BNP (230.51±52.39 vs 228.44±38.56, P>0.05) of mice in the Sham group, indicating that sham surgery would not lead to an increase in heart failure markers; compared with the Sham group, the peripheral serum BNP (165.00±9.29 vs 27.65±6.24, P<0.0001) and NT-pro BNP of mice in the TAC group were significantly increased (1543.70±97.16 vs 230.51±52.39, P<0.0001), indicating that heart failure occurred in the TAC group and the model was successfully established; compared with the TAC group, the BNP (114.10±5.08 vs 165.00±9.29, P<0.0001) and NT-pro BNP (1088.46±60.49vs1543.70±97.16, P<0.0001) were significantly decreased, indicating that compound CB-839 can significantly improve the clinical symptoms and signs of chronic heart failure, and the improvement is most obvious compared with other inhibitors.
[0098] Figure 4 A is a representative picture of HE, Masson and WGA staining of myocardial tissue of mice in each group. Figure 4 B, C, and D are statistical graphs of the staining results. Compared with the control group, the pathological score, fibrosis area percentage, and cell cross-sectional area of the Sham group did not change significantly (all P values>0.05), indicating that sham surgery did not cause myocardial tissue lesions in mice; compared with the Sham group, the pathological score, fibrosis area percentage, and cell cross-sectional area of the TAC group increased significantly (all P values<0.0001), indicating inflammatory cell infiltration, myocardial fibrosis, and myocardial cell hypertrophy in TAC mice; compared with the TAC group, the pathological score, fibrosis area percentage, and cell cross-sectional area of the TAC+CB-839 group decreased significantly (all P values<0.05), confirming that compound CB-839 can improve inflammatory cell infiltration, myocardial fibrosis, and myocardial cell hypertrophy in chronic heart failure mice, reduce myocardial tissue damage, and the improvement is most obvious compared with other glutamine inhibitors.
[0099] Figure 4E is a representative immunofluorescence image of co-staining of myocardial tissue nuclei (DAPI, blue), myocardial cells (TNI, green) and GLS1 (purple) in each group. As shown in the figure, compared with the control group, the GLS1 fluorescence intensity in the Sham group did not change significantly, indicating that the sham operation did not cause the expression of GLS1 in the myocardial tissue of mice; compared with the Sham group, the GLS1 immunofluorescence in the TAC group was enhanced, indicating that the expression of GLS1 in the myocardial cells of TAC mice increased; compared with the TAC group, the fluorescence intensity of GLS1 in the TAC+CB-839 group was significantly decreased, proving that CB-839 effectively inhibited GLS1 in the myocardial tissue of TAC mice, and other inhibitors also inhibited the expression of GLS1 to varying degrees, but compared with CB-839, the inhibitory effect was significantly weaker.
[0100] Figure 4 F and G are representative images and statistical graphs of Tunel immunofluorescence of myocardial tissue of mice in each group, respectively. As shown in the figure, compared with the control group, there was no significant difference in the number of Tunel-positive cells in the Sham group (P value>0.05), indicating that sham surgery does not lead to increased apoptosis of myocardial tissue; compared with the Sham group, the number of Tunel-positive cells in the TAC group increased significantly (P<0.0001), proving that myocardial tissue cell apoptosis increased in the TAC group; compared with the TAC group, the number of Tunel-positive cells in the TAC+CB-839 group decreased significantly (P<0.0001), proving that CB-839 can reduce myocardial tissue cell apoptosis, and other inhibitors can also reduce the number of Tunel-positive cells, but CB-839 has the most significant effect.
[0101] In summary, the results of Example 2 demonstrate that CB-839 can significantly alleviate the decline in heart function and improve clinical symptoms in chronic heart failure, and can reduce inflammatory cell infiltration, alleviate myocardial fibrosis, and reduce cell apoptosis in pathological damage, and further demonstrate that CB-839 is most effective in treating chronic heart failure compared with other glutaminase inhibitors.
[0102] Example 3
[0103] The mice with successful TAC model in Example 3 were randomly divided into 4 groups (n=5-10). In order to further prove the value of CB-839 in the preparation of chronic heart failure drugs, the positive control compound At-Ca was added in this example, and the two were administered in combination to verify the therapeutic effect of the combined drug. The experimental grouping in this example was the following 4 groups:
[0104] ①TAC group: TAC surgery was performed;
[0105] ②TAC+At-Ca group: TAC surgery was performed, and 3 mg / kg was given by gavage once a day starting from the 4th week;
[0106] ③TAC+CB-839 group: TAC surgery was performed, and 100 mg / kg was administered orally once a day starting from the 4th week;
[0107] ④TAC+At-Ca+CB-839 group: TAC surgery was performed, and At-Ca 3 mg / kg and CB-839 100 mg / kg were gavaged once a day starting from the 4th week.
[0108] The volume of the intragastric fluid for each mouse was controlled to be about 100 μL (±5 μL). The treatment steps after 8 weeks post-surgery were the same as described above, see Example 2 for details. The corresponding experimental results are shown in Tables 5-8 and Figure 5 , 6 .
[0109] Table 5 Cardiac ultrasound parameters of mice in each group in Example 3 (Mean ± SEM, n = 5)
[0110] project LVEF (%) LVFS(%) LVDEV(μL) LVPW;d(mm) TAC 31.01±2.98 20.48±1.93 34.53±3.64 2.88±0.08 TAC+At-Ca <![CDATA[42.25±1.63 *** ]]> <![CDATA[29.02±1.35 *** ]]> <![CDATA[48.82±2.17 *** ]]> <![CDATA[1.91±0.15 **** ]]> TAC+CB-839 46.78±1.73 29.19±1.68 48.39±2.02 1.97±0.13 TAC+At-Ca+CB-839 <![CDATA[73.72±4.01 ### ]]> <![CDATA[42.64±1.75 #### ]]> <![CDATA[72.84±2.99 #### ]]> <![CDATA[0.62±0.13 #### ]]>
[0111] ***P<0.001vs TAC, ****P<0.0001vs TAC; ###P<0.001vs TAC, ####P<0.0001vs TAC+At-Ca, one-way ANOVA test.
[0112] Figure 5 A is a representative ultrasound image of each group of mice in this example. Figure 5B-E and Table 5, compared with the TAC group, the LVEF (42.25±1.63 vs 31.01±2.98, P<0.001), LVFS (29.02±1.35 vs 20.48±1.93, P<0.001), and LVDEV (48.82±2.17 vs 34.53±3.64, P<0.001) of the TAC+At-Ca group were significantly improved, while the LVPW;d (1.91±0.15 vs 2.88±0.08, P<0.0001), indicating that At-Ca can improve the cardiac function and relieve myocardial hypertrophy in mice with chronic heart failure; there was no significant statistical significance in the indicators between TAC+CB-839 and TAC+At-Ca groups (all P values >0.05), indicating that CB-839 can achieve the same therapeutic effect as At-Ca; further, compared with TAC+At-Ca group, LVEF (73.72±4.01 vs 42.25±1.63, P<0.001), LVFS (42.64±1.75 vs 29.02±1.35, P<0.0001), LVDEV (72.84±2.99 vs 48.82±2.17, P<0.001) increased again in TAC+At-Ca+CB-839 group, and LVPW;d (0.62±0.13 vs 1.91±0.15, P<0.0001) decreased significantly, which proved that the combined use of the two drugs was better than single use of the drugs, and the therapeutic effect of the combined use was about 3 times that of single use of the drugs.
[0113] Table 6 Heart weight / body weight index of mice in each group (n=5)
[0114]
[0115]
[0116] ***P<0.001vs TAC; #####P<0.0001vs TAC+At-Ca, one-way ANOVA test.
[0117] As shown in Table 6 and Figure 5As shown in F, compared with the TAC group, the heart weight / body weight index (mg / g) of the TAC+At-Ca group (5.08±0.19 vs 5.66±0.18, P<0.001) was significantly reduced, indicating that At-Ca can improve the heart enlargement of mice with chronic heart failure; there was no significant statistical significance between the TAC+CB-839 group and the TAC+At-Ca group (P>0.05), indicating that CB-839 can achieve basically the same therapeutic effect as At-Ca; compared with the TAC+At-Ca group, the heart weight / body weight index (mg / g) of the TAC+At-Ca+CB-839 group (3.90±0.10 vs 5.08±0.19, P<0.0001) was further decreased, indicating that the combination of the two drugs had more obvious improvement.
[0118] Table 7 Maximum running distance of mice in each group (n=10)
[0119] project TAC TAC+At-Ca TAC+CB-839 TAC+At-Ca+CB-839 Maximum running distance (m) 80.72±6.35 <![CDATA[121.28±7.62 **** ]]> 124.76±6.76 <![CDATA[204.17±11.44 #### ]]>
[0120] ****P<0.0001vs TAC; ####P<0.0001vs TAC+At-Ca, one-way ANOVA test.
[0121] As shown in Table 7 and Figure 5 As shown in G, compared with the TAC group, the maximum running distance of the TAC+At-Ca group (121.28±7.62 vs 80.72±6.35, P<0.0001) was significantly increased, proving that At-Ca can improve the activity tolerance and physical strength of mice with chronic heart failure; there was no significant statistical significance between the TAC+CB-839 group and the TAC+At-Ca group (P>0.05), proving that the therapeutic effect of CB-839 was similar to that of At-Ca; compared with the TAC+At-Ca group, the maximum running distance of the TAC+At-Ca+CB-839 group (204.17±11.44 vs 121.28±7.62, P<0.0001) was further increased, and the improvement effect was about 3 times that of the single drug, proving that the physical strength increased more significantly with the combined use of the two drugs, and the clinical symptoms were further significantly alleviated.
[0122] Table 8 Peripheral serum heart failure markers brain natriuretic peptide (BNP) and amino-terminal pro-brain natriuretic peptide (NT-proBNP) values in each group of mice (n=10)
[0123] project TAC TAC+At-Ca TAC+CB-839 TAC+At-Ca+CB-839 BNP (pg / mL) 169.65±6.57 <![CDATA[129.00±6.91 **** ]]> 133.33±7.09 <![CDATA[43.50±10.03 #### ]]> NT-pro BNP (pg / mL) 1453.70±68.18 <![CDATA[1040.52±57.03 **** ]]> 1058.78±74.77 <![CDATA[164.16±51.62 #### ]]>
[0124] ****P<0.0001vs TAC; #P<0.05vs TAC+At-Ca, ####P<0.0001vs TAC+At-Ca, one-way ANOVA test.
[0125] As shown in Table 8 and Figure 5 As shown in H and I, compared with the TAC group, the peripheral serum BNP (129.00±6.91 vs 169.65±6.57, P < 0.0001) and NT-pro BNP (1040.52±57.03 vs 1453.70±68.18, P < 0.0001) in the TAC+At-Ca group were significantly decreased, indicating that At-Ca can significantly improve the clinical symptoms and signs of heart failure; there was no significant statistical significance between the TAC+CB-839 group and the TAC+At-Ca group (P > 0.05), indicating that the therapeutic effect of CB-839 was equivalent to that of At-Ca; compared with the TAC+At-Ca group, the peripheral serum BNP (43.50±10.03 vs 129.00±6.91, P < 0.0001) and NT-pro BNP (1040.52±57.03 vs 1453.70±68.18, P < 0.0001) in the TAC+At-Ca group were significantly decreased. BNP (164.16±51.62vs 1040.52±57.03, P<0.0001) further decreased, proving that the combination of the two drugs can better improve the clinical symptoms and signs of heart failure.
[0126] Figure 6 A is a representative picture of HE, Masson and WGA staining of myocardial tissue of mice in each group. Figure 6 B, C, and D are statistical graphs of the corresponding staining results. Compared with the TAC group, the pathological score, fibrosis area ratio, and cell cross-sectional area of the TAC+At-Ca group were significantly reduced (all P values < 0.01), indicating that At-Ca can reduce inflammatory cell infiltration, myocardial fibrosis, and myocardial cell hypertrophy in heart failure myocardial tissue; compared with the TAC+At-Ca group, the above indicators of the TAC+CB-839 group were not statistically significant (all P values > 0.05), indicating that the therapeutic effect of CB-839 was not much different from that of At-Ca; compared with the TAC+At-Ca group, the pathological score, fibrosis area ratio, and cell cross-sectional area of the TAC+At-Ca+CB-839 group were further reduced (all P values < 0.0001), proving that the combined use of the two drugs can more significantly alleviate the pathological damage of myocardial heart failure (2.5 to 3.5 times).
[0127] Figure 6E and F are representative images and statistical graphs of Tunel immunofluorescence in myocardial tissue of mice in each group, respectively. Compared with the TAC group, the number of Tunel-positive cells in the TAC+At-Ca group decreased (P<0.0001), indicating that At-Ca can reduce myocardial cell apoptosis; there was no significant difference in the number of Tunel-positive cells between the TAC+CB-839 group and the TAC+At-Ca group (P>0.05), proving that the effect of CB-839 on reducing myocardial cell apoptosis was no different from that of At-Ca; compared with the TAC+At-Ca group, the number of Tunel-positive cells in the TAC+At-Ca+CB-839 group was further reduced (P<0.0001), which was 3 times less than that of the single drug, indicating that the combination of CB-839 and At-Ca can reduce myocardial cell apoptosis more significantly.
[0128] Based on the experimental results of Example 3, it is concluded that compound CB-839 has similar effects on the treatment of chronic heart failure as At-Ca, and the combination of the two will produce more significant therapeutic effects, with the improvement effect being about 3 times that of single drug use.
[0129] Example 4
[0130] In order to further determine the optimal ratio of CB-839 and At-Ca for combined use, Example 4 set the ratio within the range of appropriate dosage of CB-839 (10-200 mg / kg) and appropriate dosage of At-Ca (1-100 mg / kg) (Table 9), and the mice were treated by intragastric administration once a day with a total volume of 100 μL (±5 μL) of DMSO solvent.
[0131] Table 9 Combination therapy of CB-839 and At-Ca at different ratios
[0132] project CB-839 At-Ca Ratio (CB-839: At-Ca) Solution 1 50mg / kg 50mg / kg 1:1 Solution 2 91.67mg / kg 8.33mg / kg 11:1 Option 3 97.06mg / kg 2.94mg / kg 33:1 Option 4 99mg / kg 1mg / kg 99:1
[0133] The administration method was the same as before, starting at the 4th week after TAC and ending at the 8th week. According to this scheme, the mice were divided into 5 groups (n=5) with the administration methods shown in Table 10. End point detection indicators: cardiac ultrasound, peripheral serum alanine aminotransferase (ALT). The results are shown in Tables 11 and 12.
[0134] Table 10 Dosage
[0135] Grouping Drug administration TAC TAC+- Treatment 1 TAC+ Solution 1 Treatment II TAC+ Solution 2 Treatment Three TAC+ Solution 3 Treatment IV TAC+ Solution 4
[0136] Table 11 Cardiac ultrasound parameters of mice in each group in Example 4 (Mean ± SEM, n = 5)
[0137] project LVEF (%) LVFS(%) LVDEV(μL) LVPW;d(mm) TAC 30.41±4.22 21.82±2.07 35.01±4.76 2.79±0.17 Treatment 1 <![CDATA[40.13±2.83 ** ]]> <![CDATA[25.66±1.07 ** ]]> <![CDATA[39.46±2.15 * ]]> <![CDATA[2.26±0.19 * ]]> Treatment II <![CDATA[52.21±4.55 *** ]]> <![CDATA[32.10±1.97 *** ]]> <![CDATA[51.38±4.21 *** ]]> <![CDATA[1.83±0.18 ** ]]> Treatment Three <![CDATA[72.32±3.23 **** ]]> <![CDATA[43.18±2.51 *** ]]> <![CDATA[71.54±3.89 **** ]]> <![CDATA[0.68±0.12 **** <!-- 10 -->]]> Treatment IV <![CDATA[64.32±4.08 **** ]]> <![CDATA[40.918±3.01 **** ]]> <![CDATA[65.87±2.06 **** ]]> <![CDATA[0.99±0.13 *** ]]>
[0138] *P<0.05 vs TAC, **P<0.01 vs TAC, ***P<0.001 vs TAC, ****P<0.0001 vs TAC, one-way ANOVA test.
[0139] The ultrasound results in Table 11 show that, compared with the TAC group, the cardiac function could be improved after treatment with Schemes 1, 2, 3, and 4, but the improvement was most obvious in Scheme 3 (all P values were < 0.001), followed by Scheme 4.
[0140] Table 12 ALT in peripheral serum of mice in each group (Mean±SEM, n=5)
[0141]
[0142] ***P<0.001vs Ctrl; #P<0.01vs TAC, ##P<0.01vs TAC, ###P<0.001vs TAC, ####P<0.0001vs TAC, one-way ANOVA test.
[0143] As shown in Table 12, the ALT of mice in the TAC group was significantly increased (normal range of ALT in peripheral serum of mice: 0-40U / L), which proved that the liver function of TAC mice was impaired. After treatment, the ALT in the peripheral serum of treatment groups three (23.05±2.98 vs 61.23±8.29, P<0.001) and four (20.19±3.18 vs 61.23±8.29, P<0.0001) decreased significantly, indicating that the liver function damage was relieved, and the relief was most significant in scheme four, followed by scheme three.
[0144] The results of Example 4 show that the most significant ratio of CB-839 and At-Ca combined to improve cardiac function is 33:1, while the best ratio for protecting liver function is 99:1. However, with the ultimate goal of treating heart failure, in the absence of obvious side effects, in this example, a comprehensive evaluation is made to take 33:1 as the optimal treatment configuration ratio, and appropriate adjustments can be made based on this ratio.
[0145] The above embodiments are only used to help illustrate the present invention. The implementation methods of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. Application of CB-839 in the preparation of drugs for the treatment of heart failure.
2. Use of a composition containing CB-839 in the preparation of a drug for treating heart failure.
3. Application of CB-839 and atorvastatin calcium in the preparation of drugs for the treatment of heart failure.
4. Use of a composition containing CB-839 and atorvastatin calcium in the preparation of a drug for treating heart failure.
5. The use according to claim 3 or 4, characterized in that: The mass ratio of CB-839 to atorvastatin calcium is 1-100:
1.
6. The use according to claim 3 or 4, characterized in that: The mass ratio of CB-839 to atorvastatin calcium is 30-100:
1.
7. A drug for treating heart failure, characterized in that: Contains CB-839 and atorvastatin calcium.
8. The drug for treating heart failure according to claim 7, characterized in that: It also contains excipient ingredients that are acceptable in pharmaceuticals.
9. The drug according to claim 7 or 8, characterized in that: The mass ratio of CB-839 to atorvastatin calcium is 1-100:
1.
10. The drug according to claim 7 or 8, characterized in that: The mass ratio of CB-839 to atorvastatin calcium is 30-100:1.
